TheWealthWeb

ICICI Prudential Nifty Pharma Index Fund Direct Growth

ICICI Prudential Mutual FundOther Scheme - Index FundsDirect · Growth

NAV ₹22.0903 on 13 November 2026

AMFI name: ICICI Prudential Nifty Pharma Index Fund - Direct Plan - Growth · Scheme code 150930 · ISIN INF109KC11M9

1 year
+25.92%
3 years, a year
+22.66%
Since launch, a year
+22.64%
NAV performance, last year

Returns

To 13 November 2026. Up to 1 year: total change. 3 and 5 years: compound return a year.

PeriodThis fundNIFTY PHARMA TRI
1M+10.86%+9.46%
6M+16.01%+19.86%
1Y+25.92%+26.54%
3Y+22.66%+23.39%
5Y-+16.53%

Benchmark: NIFTY PHARMA TRI (total return index), measured over the same dates.

Risk

From daily NAVs. Alpha, beta and capture are measured against NIFTY PHARMA TRI.

Volatility
15.29%
Annualised, 3 years
Max drawdown
-16.59%
Worst fall from a peak, 3 years
Sharpe ratio
1.09
Return above the risk-free rate per unit of volatility, 3 years
Sortino ratio
1.57
Like Sharpe, counting only falls, 3 years
Alpha
-0.59%
Return a year beyond what beta explains, 3 years
Beta
1.00
1.00 moves in step with the benchmark, 3 years
Upside capture
99%
Share of the benchmark's rises captured, 3 years
Downside capture
100%
Share of the benchmark's falls taken (lower is better), 3 years

Every 3-year holding period

Worst
+18.24%
Median
+23.04%
Best
+25.89%
Ended positive
100.0%

Compound return a year for each 3-year window in the NAV history we hold. Less sensitive to the end date than a single 3-year figure.

Costs and fund facts

Exit load
Nil
Fund size (all plans)
₹151 CrAverage, quarter to September 2026
Benchmark
NIFTY PHARMA TRI
Allotment date
14 December 2022Scheme document
Type
Open Ended
AMFI scheme code
150930

Fund managers (3)

  • Nishit Patel
  • Ashwini Bharucha
  • Venus Ahuja

How each manager has done since taking over: fund manager scorecard.

Investment objective

The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.

From the scheme summary document filed with AMFI.

SIP calculator

A monthly SIP replayed on this fund's actual daily NAVs: what it would be worth today.

Monthly SIP Amount₹10,000
Investment Horizon5 Years
Simulating monthly 1st from 15 Dec 2022 to 13 Nov 2026
Total Invested48 mos
₹4,80,000
Units: 33,208.414
Current Portfolio Value
₹7,33,584
At latest recorded NAV
Total Profit
+₹2,53,584
+52.8% absolute return
SIP XIRR
22.13%
Annualised, money-weighted
Wealth CompositionProfit is 53% of total invested capital
Invested: ₹4,80,000Profit Generated: ₹2,53,584
Same SIP in the benchmark (NIFTY PHARMA TRI)Same dates & amounts
Scheme SIP Valuation
₹7,33,584
22.1% XIRR
Benchmark SIP Valuation
₹10,34,998
21.3% XIRR
Fund minus benchmark
₹-3,01,414
Over 48 monthly installments
SIP instalments are bought on the first NAV date of each month; values use the latest NAV we hold. Past returns are not a guide to future returns.

About this fund

ICICI Prudential Nifty Pharma Index Fund Direct Growth is a mutual fund scheme from ICICI Prudential Mutual Fund, listed by AMFI under “Other Scheme - Index Funds”. This page covers the Direct plan with the Growth option. Its NAV was ₹22.0903 on 13 November 2026. It returned 25.92% over 1 year and 22.66% a year over 3 years, measured from NAVs (3- and 5-year figures are annualised). Its benchmark, NIFTY PHARMA TRI, returned 23.39% a year over 3 years. For an index fund or ETF, how closely it tracks its index matters more than its rank against other passive funds. Its average assets under management were ₹151 Cr across all plans for the quarter ending September 2026, as reported to AMFI. Managed by Nishit Patel, Ashwini Bharucha and Venus Ahuja. Its scheme summary document gives the allotment date as 14 December 2022.

Figures are calculated from AMFI NAVs and index data, not taken from fund factsheets. Methodology. Past performance is not a guide to future returns. Compare tracking difference across index funds.